Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Mimi Tran

Nurse Practitioner, Family Wichita, KS Nurse Practitioner

NPI 1396497905 CMS profile 11310752

9300 E 29Th St N Ste 204, Wichita, KS 67226

Open in the dashboard

General payments

$6,383

377 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mimi Tran of Wichita, KS is reported in the CMS Open Payments database as having received $6,383 across 377 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,025 77
2024 General $2,137 122
2023 General $2,098 112
2022 General $1,123 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mimi Tran
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Mimi Tran were reported at $1,025. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Mimi Tran Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $1,123 $141 $44–$430 $149
2023 $2,098 $154 $49–$476 $160
2024 $2,137 $165 $51–$504 $164
2025 $1,025 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Lilly USA, LLC $1,272 62 payments
  2. Dexcom, Inc. $763 57 payments
  3. Novo Nordisk Inc $697 42 payments
  4. Amgen Inc. $568 21 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $461 32 payments
  6. Insulet Corporation $373 46 payments
  7. Recordati_Rare_Diseases_Inc. $329 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $243 14 payments
  9. AstraZeneca Pharmaceuticals LP $213 7 payments
  10. Corcept Therapeutics $211 18 payments
  11. Other $1,253 63 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,358 376 payments
  2. Education $25 1 payment
Products named General payments · program years 2022–2025
  1. MOUNJARO $922 42 payments
  2. Dexcom G6 Transmitter $763 57 payments
  3. EVENITY $469 16 payments
  4. Kerendia $461 32 payments
  5. Ozempic $412 26 payments
  6. RYBELSUS $404 25 payments
  7. Omnipod $373 46 payments
  8. ZEPBOUND $354 19 payments
  9. ISTURISA $329 15 payments
  10. SIGNIFOR LAR $305 14 payments
  11. Other $3,393 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,331

Median for Nurse Practitioner: 389

Drug cost

$1,174,026

Median for Nurse Practitioner: $21,885

Branded share of claims

69.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 267 $325,107
Jardiance Empagliflozin Brand 206 $178,506
Mounjaro Tirzepatide Brand 123 $137,845
Tresiba Flextouch U-200 Insulin Degludec Brand 99 $111,326
Trulicity Dulaglutide Brand 86 $99,870
Tresiba Flextouch U-100 Insulin Degludec Brand 126 $72,305
Januvia Sitagliptin Phosphate Brand 46 $45,064
Teriparatide Generic 11 $26,786
Farxiga Dapagliflozin Propanediol Brand 27 $25,446
Humalog Kwikpen U-200 Insulin Lispro Brand 15 $23,223

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$57,676

Medicare's payments for the services billed

Medicare patients

277

Average age 72

Services billed

1,799

193 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 62%
Arthritis 45%
Chronic kidney disease 37%
Ischemic heart disease 35%
Depression 30%
Atrial fibrillation 21%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $237
$237 123 —
ZEPBOUND
  • Lilly USA, LLC $192
$192 — —
Korlym
  • Corcept Therapeutics $180
$180 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $162
$162 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

377 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record